Eli Lilly announces $1.4bn acquisition of POINT Biopharma in radiopharmaceutical domain
Eli Lilly and Company (NYSE: LLY) is set to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT), a leading radiopharmaceutical firm, marking a significant leap in cancer treatment innovations. This acquisition integrates POINT Biopharma Global’s radioligand therapies, which precisely target cancer cells, promising enhanced tumor efficacy and minimized impact on healthy tissues. POINT Biopharma Global’s cutting-edge […]